{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:29:46Z","timestamp":1795058986511,"version":"4.10.2"},"reference-count":69,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>About half of the world\u2019s population is at risk of dengue infection. Epidemics of dengue fever have caused an increased risk of morbidity and mortality in recent years, which led to the exploration of vaccines as a preventive measure. This systematic review and meta-analysis aimed to evaluate the efficacy, immune response, and safety of dengue vaccines in children by analyzing clinical trials. The review followed standard procedures for data extraction using PRISMA guidelines and searching multiple databases, including PubMed, CINAHL, Medline, Health Source, Science Direct, and Academic Search Premiere. Eligible studies involved children (0\u201317 years old). Quality assessment was analyzed using the Cochrane Collaboration criteria, while data synthesis was conducted using thematic analysis and meta-analysis. Among the 38 selected studies, dengue vaccines showed varying efficacy against all four serotypes. The CYD-TDV (Dengvaxia\u00ae) and Tekade (TAK-003) vaccines showed strong protection against severe dengue, but their long-term efficacy varied. Vaccines triggered satisfactory immune responses, notably in those previously exposed to dengue. Safety profiles were mostly favorable, noting mild adverse events post-vaccination. Meta-analysis supported vaccine efficacy and immune response, but safety concerns warrant further exploration. In conclusion, dengue vaccines showed promising efficacy and immune response, particularly against severe manifestations.<\/jats:p>","DOI":"10.3390\/diseases12020032","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T05:36:43Z","timestamp":1707197803000},"page":"32","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dengue Fever Epidemics and the Prospect of Vaccines: A Systematic Review and Meta-Analysis Using Clinical Trials in Children"],"prefix":"10.3390","volume":"12","author":[{"given":"Ebele C.","family":"Okoye","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College of Health Sciences, Jackson State University, Jackson, MS 39217, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4238-7322","authenticated-orcid":false,"given":"Amal K.","family":"Mitra","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College of Health Sciences, Jackson State University, Jackson, MS 39217, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terica","family":"Lomax","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College of Health Sciences, Jackson State University, Jackson, MS 39217, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Nunaley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College of Health Sciences, Jackson State University, Jackson, MS 39217, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13071-018-2643-9","article-title":"Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: A systematic review","volume":"11","year":"2018","journal-title":"Parasites Vectors"},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2023, December 18). Dengue and Severe Dengue. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mjafi.2014.09.011","article-title":"Discovery of the fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control","volume":"71","author":"Mustafa","year":"2015","journal-title":"Med. J. Armed Forces India"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3390\/v3122374","article-title":"The human antibody response to dengue virus infection","volume":"3","author":"Wahala","year":"2011","journal-title":"Viruses"},{"key":"ref_6","unstructured":"Centers for Disease Control & Prevention (CDC) (2023, September 18). Dengue: Clinical Presentation, Available online: https:\/\/www.cdc.gov\/dengue\/healthcare-providers\/clinical-presentation.html#:~:text=Severe%20dengue%20is%20defined%20by,impaired%20consciou-sness%2C%20or%20heart%20impairment."},{"key":"ref_7","unstructured":"Houtman, J., Shultz, L., Glassman, R., Gilmour, J., Rivera, J.M., and Scarpino, S. (2023). The Increasing Burden of Dengue Fever in a Changing Climate, The Rockefeller Foundation. Available online: https:\/\/www.rockefellerfoundation.org\/blog\/the-increasing-burden-of-dengue-fever-in-a-changing-climate\/#:~:text=In%20the%20last%20fifty%20years,are%20at%20risk%20of%20infection."},{"key":"ref_8","unstructured":"Centers for Disease Control & Prevention (CDC) (2023, October 20). Potential Range of Aedes aegypti and Aedes albopictus in the United States in 2017, Available online: https:\/\/www.cdc.gov\/mosquitoes\/mosquito-control\/professionals\/range.html#:~:text=These%20mosquitoes%20live%20in%20tropical,than%20other%20types%20of%20mosquitoes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1042\/ETLS20180123","article-title":"Climate change and the rising infectiousness of dengue","volume":"3","author":"Tozan","year":"2019","journal-title":"Emerg. Top. Life Sci."},{"key":"ref_11","unstructured":"World Health Organization (WHO) (2023, September 14). Disease Outbreak News; Dengue in Bangladesh. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON481."},{"key":"ref_12","unstructured":"PAHO (2023, December 18). Epidemiological Update: Dengue. PAHO\/WHO, Washington 2019. Available online: https:\/\/www.paho.org\/sites\/default\/files\/2019-10\/2019-sept-13-phe-dengue-epi-update.pdf."},{"key":"ref_13","unstructured":"WHO (2023, December 18). Dengue\u2014The Region of the Americas. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON475#:~:text=Dengue%20is%20the%20arbovirus%20that,were%20recorded%20in%20South%20America."},{"key":"ref_14","unstructured":"World Health Organization (WHO) (2023, November 28). Vaccines and Immunization: Dengue. Available online: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/dengue-vaccines."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1038\/emi.2016.74","article-title":"Vaccines, and immunization strategies for dengue prevention","volume":"5","author":"Liu","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.clinthera.2017.07.001","article-title":"Progress and works in progress: Update on flavivirus vaccine development","volume":"39","author":"Collins","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S1473-3099(16)30471-6","article-title":"Prevention and control of dengue\u2014The light at the end of the tunnel","volume":"17","author":"Pang","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3389\/fimmu.2018.01919","article-title":"Recent developments in recombinant protein-based dengue vaccines","volume":"9","author":"Tripathi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: Preclinical, industrial, and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits, and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14760584.2017.1276831","article-title":"Consider stopping dengvaxia administration without immunological screening","volume":"16","author":"Aguiar","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"Halstead","year":"2017","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1473-3099(17)30752-1","article-title":"Dengvaxia: Age as surrogate for serostatus","volume":"18","author":"Aguiar","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1016\/j.vaccine.2015.11.022","article-title":"Development of a recombinant, chimeric tetravalent dengue vaccine candidate","volume":"33","author":"Osorio","year":"2015","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000100"},{"key":"ref_27","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2023). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023), Cochrane."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., and Green, S. (2008). Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series, The Cochrane Collaboration.","DOI":"10.1002\/9780470712184"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Thomas, J., and Harden, A. (2008). Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med. Res. Methodol., 8.","DOI":"10.1186\/1471-2288-8-45"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/cid\/ciab288","article-title":"Analysis of hospitalized and severe dengue cases over the 6 years of follow-up of the tetravalent dengue vaccine (CYD-TDV) efficacy trials in Asia and Latin America","volume":"73","author":"Forrat","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.humimm.2021.09.006","article-title":"Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand","volume":"83","author":"Thomas","year":"2022","journal-title":"Hum. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Espa\u00f1a, G., Hogea, C., Guignard, A., ten Bosch, Q.A., Morrison, A.C., Smith, D.L., Scott, T.W., Schmidt, A., and Perkins, T.A. (2019). Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210041"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cid\/cix766","article-title":"Dependency of vaccine efficacy on preexposure and age: A closer look at a tetravalent dengue vaccine","volume":"66","author":"Yang","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.vaccine.2016.04.028","article-title":"Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction","volume":"34","author":"Plennevaux","year":"2016","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/cid\/cix966","article-title":"Impact of dengue vaccination on serological diagnosis: Insights from phase III dengue vaccine efficacy trials","volume":"66","author":"Plennevaux","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/infdis\/jiw297","article-title":"Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents Aged 2\u201316 years in Asia and Latin America","volume":"214","author":"Coudeville","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4269\/ajtmh.13-0663","article-title":"Prospective cohort study with active surveillance for fever in four dengue-endemic countries in Latin America","volume":"93","author":"Dayan","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2020.03.029","article-title":"Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination","volume":"225","author":"Biswal","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: A randomized, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year Efficacy and Safety of Takeda\u2019s Dengue Vaccine Candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4269\/ajtmh.22-0673","article-title":"Effect of the tetravalent dengue vaccine TAK-003 on sequential episodes of symptomatic dengue","volume":"108","author":"Biswal","year":"2023","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/INF.0000000000002580","article-title":"Secondary analysis of the efficacy and safety trial data of the tetravalent dengue vaccine in children and adolescents in Colombia","volume":"39","author":"Reynales","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1016\/j.vaccine.2021.07.042","article-title":"Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: A case-control study","volume":"39","author":"Ylade","year":"2021","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomized, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomized, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"E8378","DOI":"10.1073\/pnas.1714250115","article-title":"Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","volume":"115","author":"Juraska","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2\u201317 years in Asia and Latin America: 18-month interim data from a phase 2, randomized, placebo-controlled study","volume":"18","author":"Tricou","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents, and adults in a dengue-endemic country: Randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/infdis\/jiaa406","article-title":"Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: A randomized, placebo-controlled, phase 2 study","volume":"225","author":"Sirivichayakul","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1016\/j.vaccine.2013.10.013","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2\u201311 years in Malaysia: A randomized, placebo-controlled, Phase III study","volume":"31","author":"Hss","year":"2013","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1080\/21645515.2017.1333211","article-title":"Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination","volume":"13","author":"Vigne","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: A randomized, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4269\/ajtmh.15-0659","article-title":"Long-term safety and immunogenicity of a tetravalent live-attenuated dengue vaccine and evaluation of a booster dose administered to healthy Thai children","volume":"94","author":"Watanaveeradej","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.26633\/RPSP.2021.67","article-title":"Immunogenicity, and safety of a tetravalent dengue vaccine in dengue-na\u00efve adolescents in Mexico City","volume":"45","author":"Biswal","year":"2021","journal-title":"Rev. Panam. Salud Publica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety, and immunogenicity of a recombinant tetravalent dengue vaccine in 9\u201316-year-olds: A randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.vaccine.2013.08.088","article-title":"Safety, and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA","volume":"31","author":"Dayan","year":"2013","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Hadinegoro","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kriengsak, L., Chanthavanich, P., Lee, K.S., Lee, J.-S., Chatchen, S., Lim, S.-K., Arunsodsai, W., Yoon, I.-K., and Lim, J.K. (2022). Dengue virus seroprevalence study in Bangphae district, Ratchaburi, Thailand: A cohort study in 2012\u20132015. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010021"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three-dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2\u201311-year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru","volume":"30","author":"Lanata","year":"2012","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0009922814548838","article-title":"Parents\u2019 choices and rationales for alternative vaccination schedules: A qualitative study","volume":"54","author":"Saada","year":"2015","journal-title":"Clin. Pediatr."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Harmsen, I.A., Mollema, L., Ruiter, R.A., Paulussen, T.G., de Melker, H.E., and Kok, G. (2013). Why parents refuse childhood vaccination: A qualitative study using online focus groups. BMC Public Health, 13.","DOI":"10.1186\/1471-2458-13-1183"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/2\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:55:41Z","timestamp":1760104541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/2\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["diseases12020032"],"URL":"https:\/\/doi.org\/10.3390\/diseases12020032","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}